MX339077B - Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas. - Google Patents

Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.

Info

Publication number
MX339077B
MX339077B MX2011011190A MX2011011190A MX339077B MX 339077 B MX339077 B MX 339077B MX 2011011190 A MX2011011190 A MX 2011011190A MX 2011011190 A MX2011011190 A MX 2011011190A MX 339077 B MX339077 B MX 339077B
Authority
MX
Mexico
Prior art keywords
methods
treating
bacterial infection
quinolones
fluoro
Prior art date
Application number
MX2011011190A
Other languages
English (en)
Other versions
MX2011011190A (es
Inventor
Mike Dudley
David Griffith
Olga Rodny
Original Assignee
Mpex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43011488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX339077(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mpex Pharmaceuticals Inc filed Critical Mpex Pharmaceuticals Inc
Publication of MX2011011190A publication Critical patent/MX2011011190A/es
Publication of MX339077B publication Critical patent/MX339077B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen en la presente métodos para tratar una infección bacteriana pulmonar que comprende el desarrollo de bacterias bajo condiciones anaeróbicas utilizando un antibiótico de fluoroquinolona. El antibiótico de fluoroquinolona puede por ejemplo, ser levofloxacina o ofloxacina. También se describen métodos para inhibir el desarrollo de bacterias bajo condiciones anaeróbicas al exponer las bacterias a una cantidad de antibiótico de fluoroquinolona efectiva para inhibir el desarrollo de dichas bacterias.
MX2011011190A 2009-04-24 2010-04-22 Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas. MX339077B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17262509P 2009-04-24 2009-04-24
PCT/US2010/032128 WO2010124141A1 (en) 2009-04-24 2010-04-22 Methods of treating a pulmonary bacterial infection using fluoro-quinolones

Publications (2)

Publication Number Publication Date
MX2011011190A MX2011011190A (es) 2012-02-13
MX339077B true MX339077B (es) 2016-05-10

Family

ID=43011488

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011190A MX339077B (es) 2009-04-24 2010-04-22 Metodos para tratar una infeccion bacteriana pulmonar utilizando fluoro-quinolonas.

Country Status (27)

Country Link
US (2) US20120035166A1 (es)
EP (1) EP2421539B1 (es)
JP (2) JP6179844B2 (es)
KR (1) KR20120034626A (es)
CN (2) CN107050032A (es)
AU (1) AU2010238765B2 (es)
BR (1) BRPI1006626B8 (es)
CA (1) CA2759874C (es)
CL (1) CL2011002649A1 (es)
CO (1) CO6450642A2 (es)
CY (1) CY1122525T1 (es)
DK (1) DK2421539T3 (es)
ES (1) ES2755754T3 (es)
HR (1) HRP20191951T1 (es)
HU (1) HUE046595T2 (es)
IL (1) IL215777A (es)
LT (1) LT2421539T (es)
MX (1) MX339077B (es)
MY (1) MY178871A (es)
NZ (1) NZ596245A (es)
PL (1) PL2421539T3 (es)
PT (1) PT2421539T (es)
RU (1) RU2535056C2 (es)
SG (3) SG175288A1 (es)
SI (1) SI2421539T1 (es)
WO (1) WO2010124141A1 (es)
ZA (1) ZA201107903B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524734B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
ES2809177T3 (es) 2008-10-07 2021-03-03 Horizon Orphan Llc Inhalación de levofloxacino para reducir la inflamación pulmonar
CA2773033C (en) 2009-09-04 2016-10-11 Mpex Pharmaceuticals, Inc. Use of aerosolized levofloxacin for treating cystic fibrosis
US9572774B2 (en) 2011-05-19 2017-02-21 Savara Inc. Dry powder vancomycin compositions and associated methods
US9861616B2 (en) * 2013-03-14 2018-01-09 Cempra Pharmaceuticals, Inc. Methods for treating respiratory diseases and formulations therefor
JP6966835B2 (ja) * 2016-02-05 2021-11-17 ホライズン オーファン リミテッド ライアビリティ カンパニー 嚢胞性線維症のためのフルオロキノロン製剤
CN108849939B (zh) * 2018-07-31 2021-02-19 广东省农业科学院植物保护研究所 盐酸左氧氟沙星在制备用于防治烟草青枯病的农药制剂中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075890A1 (en) * 2002-03-05 2003-09-18 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
RU2255757C1 (ru) * 2004-06-22 2005-07-10 Санкт-Петербургская Общественная Организация "Санкт-Петербургский Институт Биорегуляции И Геронтологии Сзо Рамн" Пептидное соединение, восстанавливающее функцию органов дыхания
US7838532B2 (en) 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
PT1901749T (pt) * 2005-05-18 2016-11-04 Raptor Pharmaceuticals Inc Fluoroquinolonas aerossolizadas e suas utilizações
JP5727927B2 (ja) * 2008-05-15 2015-06-03 ノバルティス アーゲー フルオロキノロンの肺送達
JP2012505223A (ja) * 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物

Also Published As

Publication number Publication date
RU2011145430A (ru) 2013-05-27
IL215777A (en) 2017-09-28
WO2010124141A1 (en) 2010-10-28
AU2010238765A1 (en) 2011-11-10
CY1122525T1 (el) 2021-01-27
SG10201811494SA (en) 2019-01-30
JP6228580B2 (ja) 2017-11-08
US20210015811A1 (en) 2021-01-21
MX2011011190A (es) 2012-02-13
HRP20191951T1 (hr) 2021-05-14
SG175288A1 (en) 2011-11-28
IL215777A0 (en) 2012-01-31
CO6450642A2 (es) 2012-05-31
PT2421539T (pt) 2019-11-22
BRPI1006626B1 (pt) 2021-05-11
AU2010238765B2 (en) 2014-12-18
CA2759874C (en) 2016-11-08
HUE046595T2 (hu) 2020-03-30
CL2011002649A1 (es) 2012-06-22
EP2421539A4 (en) 2014-01-29
CN102427815A (zh) 2012-04-25
LT2421539T (lt) 2019-12-10
MY178871A (en) 2020-10-21
US20120035166A1 (en) 2012-02-09
KR20120034626A (ko) 2012-04-12
PL2421539T3 (pl) 2020-02-28
RU2535056C2 (ru) 2014-12-10
ES2755754T3 (es) 2020-04-23
JP6179844B2 (ja) 2017-08-16
BRPI1006626B8 (pt) 2021-05-25
SI2421539T1 (sl) 2019-12-31
JP2012524811A (ja) 2012-10-18
EP2421539A1 (en) 2012-02-29
ZA201107903B (en) 2013-01-30
SG10201403512TA (en) 2014-08-28
EP2421539B1 (en) 2019-10-23
JP2016053041A (ja) 2016-04-14
DK2421539T3 (da) 2019-11-18
NZ596245A (en) 2013-11-29
BRPI1006626A2 (pt) 2020-07-28
CA2759874A1 (en) 2010-10-28
CN107050032A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
MY178871A (en) Methods of treating a pulmonary bacterial infection using fluoro-quinolones
MY174523A (en) ?-lactamase inhibitor and process for preparing the same
EP3409666A3 (en) Seca inhibitors and methods of making and using thereof
WO2012135016A3 (en) Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
NZ593111A (en) Antibacterial compounds
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
NZ708928A (en) Mannose derivatives for treating bacterial infections
MX366793B (es) Metodos para preparar oxazolidinonas y composiciones que las contienen.
MX2012002759A (es) Compuestos quimicos.
WO2018208987A3 (en) Antibacterial compounds
MX2013008162A (es) Inhibidores de pirimidina y topoisomerasa iv.
MX2021003084A (es) Compuestos antibacterianos.
CA2710814C (en) Bacterial ghost (bg) production process using betapropiolactone (blp) for final inactivation
WO2012103295A3 (en) Small molecule rnase inhibitors and methods of use
WO2014022382A3 (en) Antibacterial protein kinase inhibitors
IL287931A (en) Bioreactors for the growth of microorganisms
IL284678A (en) Bioreactors for growing microorganisms
IN2012DN03846A (es)
NZ713357A (en) Antimicrobial compounds and methods of making and using the same
MX2021001564A (es) Diazabiciclooctanonas como inhibidores de serina beta-lactamasas.
MY156304A (en) 5-hydroxymethyl-oxazolidin-2-one derivatives for treating bacterial intestinal diseases
EA201170121A1 (ru) Лечение инфекций, вызванных антибиотикоустойчивыми бактериями
WO2011076912A3 (en) Methods and compositions for biologically controlling microbial growth on clean room equipment
WO2009137133A3 (en) 5-substituted-2-imino-thiazolidinone compounds and their use as inhibitors of bacterial infection
MX2015001817A (es) Inhibicion de objetivos antimicrobianos con potencial reducido para la resistencia.

Legal Events

Date Code Title Description
FG Grant or registration